Labiotech.eu

In Depth 3 Nov 2022

What’s on the horizon for gene editing-based therapies?

Gene editing has come far in the past decade. However, the field is still finding its feet regarding challenges such as drug delivery, regulation and competition with first-generation gene therapies. Gene editing is a sizzling hot topic in the biotech industry, powered by advances in genetic tools such as CRISPR, TALENs and zinc-finger nucleases. Gene […]

November 3, 2022 - 8 minutesmins - By Jonathan Smith

Biocomposites Ltd shutterstock diabetic foot ulcer

News and Trends 3 Nov 2022

New method to treat diabetic foot ulcers revealed by Biocomposites Ltd

Diabetic foot infection costs the UK’s NHS around £900 million ($990 million) a year, bringing severe misery to patients. Usually, systemic antibiotics are routinely given to those with diabetes who are susceptible to infected foot ulcers. Unfortunately, effective treatment can be disrupted by complications by using this treatment due to allergic reactions, antibiotic-resistant organisms, the […]

November 3, 2022 - 3 minutesmins - By Liza Laws

News and Trends 3 Nov 2022

Positive results of cancer treatment to be presented at Boston conference

Results of a cancer treatment in the treatment of gynecologic and breast cancer are to be presented next week, November 8-12, at the Society for Immunotherapy of Cancer (SITC) conference in Boston. Alderaan Biotechnology is a preclinical biotech company that focuses on monoclonal antibody development. It will be making announcements about the most recent development […]

November 3, 2022 - 2 minutesmins - By Liza Laws

News and Trends 3 Nov 2022

Virax Biolabs introduces flu, Covid-19 and RSV rapid test kits

Rapid test kits that can accurately identify infections related to respiratory syncytial virus (RSV), influenza and Covid-19 can deliver results in 15 minutes. UK-based Virax Biolabs, a biotech company focused on the prevention, detection and diagnosis of viral diseases announced today (November 3) the distribution of a tripe virus antigen rapid test kit has been […]

November 3, 2022 - 2 minutesmins - By Liza Laws

News and Trends 3 Nov 2022

Senescent cells as vaccines against cancer?

Cancer cells have a series of features that allow the immune system to identify and attack them. However, these same cells create an environment that blocks immune cells and protects the tumor. This means immune cells cannot reach the cancer cells to remove them. The scientific community has been working to increase the effectiveness of […]

November 3, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 3 Nov 2022

Servier and OSE Immunotherapeutics complete enrollment in Sjögren’s syndrome trial

Servier and French biotech company OSE Immunotherapeutics SA have completed patient enrollment in a phase 2a clinical trial evaluating the efficacy and safety of monoclonal antibody OSE-127/S95011 in primary Sjögren’s syndrome. The international, randomized, double-blind, placebo-controlled, phase 2a study is designed to evaluate the efficacy and tolerance of the monoclonal antibody OSE-127/S95011 in primary Sjögren’s […]

November 3, 2022 - 2 minutesmins - By Jim Cornall

Impacting vaccine development: COVID-19 and its implications for the future of vaccines

The development of COVID-19 vaccines was an unprecedented achievement at a time of urgent medical need. We explore the novel technology platforms that went into their development and consider their long-term impact on vaccine research. Ever since the first vaccine against smallpox in the late 1700s, vaccines have gained a reputation as a critical tool […]

November 3, 2022 - 8 minutesmins - By Sudha Sundaram

VectorBuilder Research and Manufacturing Campus

News and Trends 2 Nov 2022

VectorBuilder to build gene delivery campus after $57M funding

Gene delivery technology company VectorBuilder Inc. has announced the completion of $57 million in funding. The funding, co-led by Legend Capital, will support the construction of VectorBuilder’s new Gene Delivery Research and Manufacturing Campus, and further boost the company’s R&D capabilities and global business presence. VectorBuilder was established in 2014 to commercialize its novel e-commerce […]

November 2, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 2 Nov 2022

Authorization given to BeiGene’s chemo-free treatment option for lymphoma

Marketing authorization has been granted to a drug to treat relapsed/refractory (R/R) marginal zone lymphoma (MZL) without chemotherapy, it was announced today (November 2). The European Commission (EC) gave the authorization to biotech company, BeiGene, for Brukinsa (zanubrutinib), which treats adults with the condition who have received at least one prior anti-CD20-based therapy. The approval […]

November 2, 2022 - 3 minutesmins - By Liza Laws

News and Trends 2 Nov 2022

Meletios Therapeutics wins €5.2M European Commission funding for SARS research

Meletios Therapeutics, a French biotech company, announced today (November 2) that it has been named one of 75 winners of the European Innovation Council (EIC) Accelerator program and will receive €5.2 million ($5.1 million) in funding from the European Commission. The company specializes in the research and development of antiviral treatments and says the funding […]

November 2, 2022 - 3 minutesmins - By Liza Laws

Startup Scout 2 Nov 2022

Breakpoint Therapeutics sabotages DNA repair in cancer cells

The Hamburg-based Evotec spinout Breakpoint Therapeutics is working on cancer treatments that block the ability of tumor cells to repair their own DNA. In the last decade, a new class of drugs known as DNA damage response (DDR) inhibitors has risen to prominence in the oncology space. These drugs are able to break down the […]

November 2, 2022 - 4 minutesmins - By Jonathan Smith

News and Trends 2 Nov 2022

CV6 Therapeutics raises $9.2M to test cancer drug

CV6 Therapeutics has secured $9.2m to progress its lead oncology asset, CV6-168, into a first-in-human phase 1a clinical trial and perform further scientific development work. CV6 Therapeutics is a drug development biotechnology company specializing in innovative small molecule therapeutics for cancer and inflammatory diseases. Investors participating in the financing include QUBIS, the commercialization arm of […]

November 2, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

What’s on the horizon for gene editing-based therapies?

New method to treat diabetic foot ulcers revealed by Biocomposites Ltd

Positive results of cancer treatment to be presented at Boston conference

Virax Biolabs introduces flu, Covid-19 and RSV rapid test kits

Senescent cells as vaccines against cancer?

Servier and OSE Immunotherapeutics complete enrollment in Sjögren’s syndrome trial

Impacting vaccine development: COVID-19 and its implications for the future of vaccines

VectorBuilder to build gene delivery campus after $57M funding

Authorization given to BeiGene’s chemo-free treatment option for lymphoma

Meletios Therapeutics wins €5.2M European Commission funding for SARS research

Breakpoint Therapeutics sabotages DNA repair in cancer cells

CV6 Therapeutics raises $9.2M to test cancer drug

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!